Report cover image

France Radiopharmaceuticals Market By Radioisotope (Technetium 99m, Fluorine 18, Iodine I, Gallium 68, Others), By Application (Cancer, Cardiology, Others), By Type (Diagnostic, Therapeutic), By End User (Hospitals and clinics, Medical Imaging centers, Ot

Publisher Allied Market Research
Published May 02, 2023
Length 81 Pages
SKU # ALMR18790419

Description

France Radiopharmaceuticals Market By Radioisotope (Technetium 99m, Fluorine 18, Iodine I, Gallium 68, Others), By Application (Cancer, Cardiology, Others), By Type (Diagnostic, Therapeutic), By End User (Hospitals and clinics, Medical Imaging centers, Others): Opportunity Analysis and Industry Forecast, 2023-2032


The France Radiopharmaceuticals Market is a quickly expanding, specialized company with an estimated market value of EUR8.4 billion in 2020. Radiopharmaceuticals are drugs which contain radioactive aspects and have both analysis and also healing abilities. These medications are used primarily to detect different conditions in the body, such as diagnosing cancer cells. The most usual kinds of radiopharmaceuticals utilized in France are Technetium-99m, Fluorine-18, Iodine I, Gallium-68, as well as others. The radiopharmaceuticals market is categorized into applications (cancer cells, cardiology, as well as others), kind (diagnostic/therapeutic), and also end individual (hospitals/clinics clinical imaging centers, and others).

The development of the France radiopharmaceuticals market is mainly driven by the rising prevalence of cancer cells and also cardiology, as well as technological improvements in the health care field. Additionally, the boosting demand for cost-efficient and also specific medical diagnosis and the boosting number of public and personal financial investments in medical imaging are important elements driving the market. Additionally, the rising need for nuclear medicine procedures with radiopharmaceuticals is developing market growth opportunities.

The France radiopharmaceuticals market is dealing with restrictions such as the high cost of scientific tests, trade obstacles, and also financial restraints. Additionally, the demand for radiation safety measures and operational restrictions are hindering the development of the France radiopharmaceuticals market.

With the assistance of brand-new modern technologies, the radiopharmaceuticals market is being changed. Because of this, the advancement of brand-new radiopharmaceutical representatives are becoming extra cost-efficient and also efficient. Additionally, many brand-new innovations are taking place in the health care sector such as individualized medicine as well as the enhancing demand for innovative imaging methods. All of this is producing market possibilities.

The affordable rivalry is solid in the France radiopharmaceuticals market because of the expanding variety of players, along with the presence of international business. The negotiating power of consumers is additionally high as there is a vast array of services and products readily available. There is also excellent bargaining power from distributors as a result of minority resources offered for manufacturing as well as the visibility of strong players out there. The risk from replacements is moderate as the primary use of radiopharmaceuticals is for analysis and therapeutic functions in the healthcare industry. There is additionally modest risk from brand-new participants as the expense of entrance is fairly high due to the high rate of examinations, scientific trials, and regulative approvals.

The future of the France radiopharmaceuticals market is expected to be driven by the raising number of federal government efforts such as the introduction of health care infrastructures, promotional activities, aids, and also initiatives to lower management costs. Additionally, the growing R&D in the pharma market and also technological improvements are expected to fuel the market development. New growths in the distribution of medicine, such as oral and also inhalation types, will produce a lot more opportunities for radiopharmaceuticals. Furthermore, there is enhancing need for individualized medications and also the introduction of artificial intelligence and also machine learning in healthcare is likewise driving the market.

The France radiopharmaceuticals market has great possible for growth as a result of the increasing number of medical trials, the accessibility of innovative techniques, and also the inexpensive of manufacturing. Furthermore, the rising awareness of radiopharmaceuticals, the expanding number of healthcare infrastructures, and also the raising need for personalized medications are developing brand-new development possibilities. Additionally, the fostering of polymerase chain reaction (PCR)- based nucleic acid testing is positioned to sustain the market in the future.

The regulating bodies such as HAS, ANSM, MRT as well as Cerba has laid out strict guidelines on the manufacturing as well as use of radiopharmaceuticals in France. The regulations remain in area to ensure the quality as well as safety and security of the radiopharmaceuticals produced as well as to guarantee the risk-free circulation and disposal of the radioactive waste. In addition, the license charges as well as scientific trial guidelines additionally require to be complied with it.

The France radiopharmaceuticals market is additional segmented based upon radioisotope (Technetium-99m, Fluorine-18, Iodine-I, Gallium-68, Others), application (Cancer cells, Cardiology, Others), kind (Diagnostic, Healing) and also end customers (Hospitals/Clinics, Medical Imaging Centers, Others). The most commonly made use of radioisotope for radiopharmaceuticals in France is Technetium-99m and the primary end-user section is health centers as well as facilities.

Key Benefits For Stakeholders

Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.

Analyze the key strategies adopted by major market players in france radiopharmaceuticals market.

Assess and rank the top factors that are expected to affect the growth of france radiopharmaceuticals market.

Top Player positioning provides a clear understanding of the present position of market players.

Detailed analysis of the france radiopharmaceuticals market segmentation assists to determine the prevailing market opportunities.

Identify key investment pockets for various offerings in the market.
New Product Development/ Product Matrix of Key Players
Patient/epidemiology data at country, region, global level
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)
SWOT Analysis

Key Market Segments

By Type

Diagnostic
Therapeutic

By End User

Hospitals and clinics
Medical Imaging centers
Others

By Radioisotope

Fluorine 18
Iodine I
Gallium 68
Others
Technetium 99m

By Application

Cancer
Cardiology
Others

Key Market Players

Progenics Pharmaceuticals
Bracco Diagnostics
Covidien
Jubilant Pharma
IBA Molecular
Curium Pharma
GE Healthcare
Cardinal Health
Novartis
Lantheus Medical Imaging

Please Note: It will take 7-10 business days to complete the report upon order confirmation. 

Table of Contents

81 Pages
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits to the Stakeholders
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Impacting Factors
3.2.2. Top Investment Pockets
3.3. Porter’s Five Forces Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: FRANCE RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE
4.1. Overview
4.1.1. Market Size and Forecast, By Radioisotope
4.2. Technetium 99m
4.3. Fluorine 18
4.4. Iodine I
4.5. Gallium 68
4.6. Others
CHAPTER 5: FRANCE RADIOPHARMACEUTICALS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market Size and Forecast, By Application
5.2. Cancer
5.3. Cardiology
5.4. Others
CHAPTER 6: FRANCE RADIOPHARMACEUTICALS MARKET, BY TYPE
6.1. Overview
6.1.1. Market Size and Forecast, By Type
6.2. Diagnostic
6.3. Therapeutic
CHAPTER 7: FRANCE RADIOPHARMACEUTICALS MARKET, BY END USER
7.1. Overview
7.1.1. Market Size and Forecast, By End User
7.2. Hospitals and clinics
7.3. Medical Imaging centers
7.4. Others
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Company 1
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Company 2
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. Company 3
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. Company 4
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Company 5
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Company 6
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. Company 7
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. Company 8
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Company 9
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. Company 10
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
9.10.7. Key strategic moves and developments
LIST OF TABLES
TABLE 01. FRANCE RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 02. FRANCE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 03. FRANCE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 04. FRANCE RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 05. COMPANY 1: KEY EXECUTIVES
TABLE 06. COMPANY 1: COMPANY SNAPSHOT
TABLE 07. COMPANY 1: OPERATING SEGMENTS
TABLE 08. COMPANY 1: PRODUCT PORTFOLIO
TABLE 09. COMPANY 1: KEY STRATERGIES
TABLE 10. COMPANY 2: KEY EXECUTIVES
TABLE 11. COMPANY 2: COMPANY SNAPSHOT
TABLE 12. COMPANY 2: OPERATING SEGMENTS
TABLE 13. COMPANY 2: PRODUCT PORTFOLIO
TABLE 14. COMPANY 2: KEY STRATERGIES
TABLE 15. COMPANY 3: KEY EXECUTIVES
TABLE 16. COMPANY 3: COMPANY SNAPSHOT
TABLE 17. COMPANY 3: OPERATING SEGMENTS
TABLE 18. COMPANY 3: PRODUCT PORTFOLIO
TABLE 19. COMPANY 3: KEY STRATERGIES
TABLE 20. COMPANY 4: KEY EXECUTIVES
TABLE 21. COMPANY 4: COMPANY SNAPSHOT
TABLE 22. COMPANY 4: OPERATING SEGMENTS
TABLE 23. COMPANY 4: PRODUCT PORTFOLIO
TABLE 24. COMPANY 4: KEY STRATERGIES
TABLE 25. COMPANY 5: KEY EXECUTIVES
TABLE 26. COMPANY 5: COMPANY SNAPSHOT
TABLE 27. COMPANY 5: OPERATING SEGMENTS
TABLE 28. COMPANY 5: PRODUCT PORTFOLIO
TABLE 29. COMPANY 5: KEY STRATERGIES
TABLE 30. COMPANY 6: KEY EXECUTIVES
TABLE 31. COMPANY 6: COMPANY SNAPSHOT
TABLE 32. COMPANY 6: OPERATING SEGMENTS
TABLE 33. COMPANY 6: PRODUCT PORTFOLIO
TABLE 34. COMPANY 6: KEY STRATERGIES
TABLE 35. COMPANY 7: KEY EXECUTIVES
TABLE 36. COMPANY 7: COMPANY SNAPSHOT
TABLE 37. COMPANY 7: OPERATING SEGMENTS
TABLE 38. COMPANY 7: PRODUCT PORTFOLIO
TABLE 39. COMPANY 7: KEY STRATERGIES
TABLE 40. COMPANY 8: KEY EXECUTIVES
TABLE 41. COMPANY 8: COMPANY SNAPSHOT
TABLE 42. COMPANY 8: OPERATING SEGMENTS
TABLE 43. COMPANY 8: PRODUCT PORTFOLIO
TABLE 44. COMPANY 8: KEY STRATERGIES
TABLE 45. COMPANY 9: KEY EXECUTIVES
TABLE 46. COMPANY 9: COMPANY SNAPSHOT
TABLE 47. COMPANY 9: OPERATING SEGMENTS
TABLE 48. COMPANY 9: PRODUCT PORTFOLIO
TABLE 49. COMPANY 9: KEY STRATERGIES
TABLE 50. COMPANY 10: KEY EXECUTIVES
TABLE 51. COMPANY 10: COMPANY SNAPSHOT
TABLE 52. COMPANY 10: OPERATING SEGMENTS
TABLE 53. COMPANY 10: PRODUCT PORTFOLIO
TABLE 54. COMPANY 10: KEY STRATERGIES
LIST OF FIGURES
FIGURE 01. FRANCE RADIOPHARMACEUTICALS MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF FRANCE RADIOPHARMACEUTICALS MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN FRANCE RADIOPHARMACEUTICALS MARKET (2023-2032)
FIGURE 04. PORTER FIVE-1
FIGURE 05. PORTER FIVE-2
FIGURE 06. PORTER FIVE-3
FIGURE 07. PORTER FIVE-4
FIGURE 08. PORTER FIVE-5
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: FRANCE RADIOPHARMACEUTICALS MARKET
FIGURE 10. FRANCE RADIOPHARMACEUTICALS MARKET,BY RADIOISOTOPE, 2022 ($MILLION)
FIGURE 11. FRANCE RADIOPHARMACEUTICALS MARKET,BY APPLICATION, 2022 ($MILLION)
FIGURE 12. FRANCE RADIOPHARMACEUTICALS MARKET,BY TYPE, 2022 ($MILLION)
FIGURE 13. FRANCE RADIOPHARMACEUTICALS MARKET,BY END USER, 2022 ($MILLION)
FIGURE 14. TOP WINNING STRATEGIES, BY YEAR
FIGURE 15. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 16. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 17. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 18. COMPETITIVE DASHBOARD
FIGURE 19. COMPETITIVE HEATMAP: FRANCE RADIOPHARMACEUTICALS MARKET
FIGURE 20. TOP PLAYER POSITIONING, 2022
FIGURE 21. COMPANY 1: NET SALES, 2020-2022* ($MILLION)
FIGURE 22. COMPANY 1: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 23. COMPANY 1: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 24. COMPANY 2: NET SALES, 2020-2022* ($MILLION)
FIGURE 25. COMPANY 2: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 26. COMPANY 2: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 27. COMPANY 3: NET SALES, 2020-2022* ($MILLION)
FIGURE 28. COMPANY 3: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 29. COMPANY 3: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 30. COMPANY 4: NET SALES, 2020-2022* ($MILLION)
FIGURE 31. COMPANY 4: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 32. COMPANY 4: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 33. COMPANY 5: NET SALES, 2020-2022* ($MILLION)
FIGURE 34. COMPANY 5: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 35. COMPANY 5: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 36. COMPANY 6: NET SALES, 2020-2022* ($MILLION)
FIGURE 37. COMPANY 6: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 38. COMPANY 6: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 39. COMPANY 7: NET SALES, 2020-2022* ($MILLION)
FIGURE 40. COMPANY 7: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 41. COMPANY 7: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 42. COMPANY 8: NET SALES, 2020-2022* ($MILLION)
FIGURE 43. COMPANY 8: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 44. COMPANY 8: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 45. COMPANY 9: NET SALES, 2020-2022* ($MILLION)
FIGURE 46. COMPANY 9: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 47. COMPANY 9: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 48. COMPANY 10: NET SALES, 2020-2022* ($MILLION)
FIGURE 49. COMPANY 10: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 50. COMPANY 10: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us